September 2025 in “International Journal of Molecular Sciences” International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
May 2025 in “Acta Dermato Venereologica” Alopecia areata patients have higher risks of infections, lymphoma, heart issues, and death.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
August 2024 in “International Journal of Molecular Sciences” Mesenchymal Stem Cell therapy shows promise for treating hair loss in Alopecia Areata.
April 2024 in “Cosmetics” Wigs help improve self-esteem and quality of life for people with hair loss from alopecia areata.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
February 2022 in “International Journal of Research in Dermatology” Tretinoin alone is more effective than combined with microdermabrasion for long-term alopecia areata treatment.
2 citations
,
May 2023 in “Photobiomodulation, photomedicine, and laser surgery” Light therapy is effective and safe for treating skin color disorders like vitiligo and dark spots.
January 2025 in “Journal of Personalized Medicine” People with Alopecia Areata are more likely to have prediabetes and obesity.
46 citations
,
April 2021 in “International Journal of Molecular Sciences” Curcumin shows promise in reducing pain and inflammation, but more research is needed.
6 citations
,
January 2015 in “Journal of regenerative medicine & tissue engineering” The review concludes that innovations in regenerative medicine, tissue engineering, and developmental biology are essential for effective tissue repair and organ transplants.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
15 citations
,
February 2021 in “Frontiers in immunology” Leptin, a hormone from fat cells, affects immune responses and can influence skin diseases and hair growth.
3 citations
,
January 2019 in “International Journal of Trichology” The article concludes that treating hair loss requires careful research, understanding the causes, and personalized treatment plans.
30 citations
,
September 2020 in “Journal of Patient-Reported Outcomes” Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.
14 citations
,
January 2019 in “PubMed” Vitamin D might be involved in the development of alopecia areata and could help in its treatment.
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
3 citations
,
January 2021 in “Journal of The American Academy of Dermatology” Different types of atopic dermatitis were linked to specific genetic and immune changes, suggesting that severe cases might need stronger immune-targeting treatments.
2 citations
,
February 2025 in “Archives of Dermatological Research” Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
1 citations
,
June 2025 in “Journal of Patient Experience” Alopecia areata greatly affects quality of life, with many experiencing mental health issues and lacking professional support.
1 citations
,
March 2025 in “Skin Appendage Disorders” Healthcare access for alopecia areata in the USA is unequal among ethnic groups.
1 citations
,
June 2023 in “Dermatology and therapy” People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.